Skip to main content
Top
Published in: BioDrugs 5/2010

01-10-2010 | Original Research Article

Carbosilane Dendrimers to Transfect Human Astrocytes with Small Interfering RNA Targeting Human Immunodeficiency Virus

Authors: Jose Luis Jiménez, María Isabel Clemente, Nick D. Weber, Javier Sanchez, Paula Ortega, F. Javier de la Mata, Rafael Gómez, Dolores García, Luis A. López-Fernández, Dr María Ángeles Muñoz-Fernández

Published in: BioDrugs | Issue 5/2010

Login to get access

Abstract

Background

HIV infection of the CNS is the principle cause of HIV-associated dementia in adults and encephalopathy in children. Gene therapy techniques such as small interfering RNA (siRNA) possess great potential in drug development, but first they must overcome the key obstacle of reaching the interior of the affected cells. A successful delivery vector for anti-HIV drugs that is capable of crossing the blood-brain barrier (BBB) could provide a way of addressing this issue. Non-viral vectors such as dendrimers offer a means for effectively delivering and transfecting siRNA to the target cells.

Objective

To evaluate the application of gene therapy for reducing HIV replication in human astrocytes.

Methods

We used the 2G-NN16 amino-terminated carbosilane dendrimer as a method for delivering siRNA to HIV-infected human astrocytes. We tested the cytotoxicity in human astrocytoma cells caused by 2G-NN16 and dendriplexes formed with siRNA (siRNA/2G-NN16) by 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyl-tetrazolium-bromide (MTT) and lactate dehydrogenase assays. The ability to transfect human astrocytes with siRNA/2G-NN16 dendriplexes was tested by flow cytometry and immunofluorescence microscopy. To assess the potential capability of siRNA/2G-NN16 dendriplexes for crossing the BBB, we used an in vitro transcytosis assay with bovine brain microvascular endothelial cells. HIV-1 inhibition assays using 2G-NN16 and siRNA/2G-NN16 dendriplexes were determined by quantification of the viral load from culture supernatants of the astrocytes.

Results

A gradual time-controlled degradation of the 2G-NN16 dendrimer and liberation of its siRNA cargo between 12 and 24 hours was observed via gel electrophoresis. There was no cytotoxicity in HIV-infected or non-infected human astrocytoma cells when treated with up to 24 μg/mL of 2G-NN16 dendrimer or siRNA/2G-NN16 dendriplexes, and siRNA/2G-NN16 dendriplexes were seen to successfully transfect human astrocytes even after crossing an in vitro BBB model. More interestingly, transfected siRNA was observed to exert a biologic effect, as dendriplexes were shown to down-regulate the housekeeping gene GAPDH and to reduce replication of HIV-1 strains X4-HIV NL4-3 and R5-HIV BaL in human astrocytes.

Conclusions

The 2G-NN16 dendrimer successfully delivers and transfects siRNA to HIV-infected human astrocytes and achieves gene silencing without causing cytotoxicity.Both authors have contributed equally to this paper.
Literature
1.
go back to reference Sacktor N, Lyles RH, Skolasky R, et al. HIV-associated neurologic disease incidence changes: multicenter AIDS cohort study, 1990–1998. Neurology 2001 Jan 23; 56(2): 257–60PubMedCrossRef Sacktor N, Lyles RH, Skolasky R, et al. HIV-associated neurologic disease incidence changes: multicenter AIDS cohort study, 1990–1998. Neurology 2001 Jan 23; 56(2): 257–60PubMedCrossRef
2.
go back to reference Lindl KA, Marks DR, Kolson DL, et al. HIV-associated neurocognitive disorder: pathogenesis and therapeutic opportunities. J Neuroimmune Pharmacol. Epub 2010 Apr 16 Lindl KA, Marks DR, Kolson DL, et al. HIV-associated neurocognitive disorder: pathogenesis and therapeutic opportunities. J Neuroimmune Pharmacol. Epub 2010 Apr 16
3.
go back to reference Ellis RJ, Deutsch R, Heaton RK, et al. Neurocognitive impairment is an independent risk factor for death in HIV infection. San Diego HIV Neurobehavioral Research Center Group. Arch Neurol 1997 Apr; 54(4): 416–24PubMedCrossRef Ellis RJ, Deutsch R, Heaton RK, et al. Neurocognitive impairment is an independent risk factor for death in HIV infection. San Diego HIV Neurobehavioral Research Center Group. Arch Neurol 1997 Apr; 54(4): 416–24PubMedCrossRef
4.
go back to reference Sanchez-Ramon S, Resino S, Bellon Cano JM, et al. Neuroprotective effects of early antiretrovirals in vertical HIV infection. Pediatr Neurol 2003 Sep; 29(3): 218–21PubMedCrossRef Sanchez-Ramon S, Resino S, Bellon Cano JM, et al. Neuroprotective effects of early antiretrovirals in vertical HIV infection. Pediatr Neurol 2003 Sep; 29(3): 218–21PubMedCrossRef
5.
go back to reference Canto-Nogues C, Sanchez-Ramon S, Alvarez S, et al. HIV-1 infection of neurons might account for progressive HIV-1-associated encephalopathy in children. J Mol Neurosci 2005; 27(1): 79–89PubMedCrossRef Canto-Nogues C, Sanchez-Ramon S, Alvarez S, et al. HIV-1 infection of neurons might account for progressive HIV-1-associated encephalopathy in children. J Mol Neurosci 2005; 27(1): 79–89PubMedCrossRef
6.
go back to reference Gonzalez-Scarano F, Martin-Garcia J. The neuropathogenesis of AIDS. Nat Rev Immunol 2005 Jan; 5(1): 69–81PubMedCrossRef Gonzalez-Scarano F, Martin-Garcia J. The neuropathogenesis of AIDS. Nat Rev Immunol 2005 Jan; 5(1): 69–81PubMedCrossRef
7.
go back to reference Kerza-Kwiatecki AP, Amini S. CNS as an HIV-1 reservoir: BBB and drug delivery. J Neurovirol 1999 Apr; 5(2): 113–4PubMedCrossRef Kerza-Kwiatecki AP, Amini S. CNS as an HIV-1 reservoir: BBB and drug delivery. J Neurovirol 1999 Apr; 5(2): 113–4PubMedCrossRef
8.
go back to reference Brew BJ. HIV, the brain, children, HAART and ‘neuro-HAART': a complex mix. Aids 2009 Sep 10; 23(14): 1909–10PubMedCrossRef Brew BJ. HIV, the brain, children, HAART and ‘neuro-HAART': a complex mix. Aids 2009 Sep 10; 23(14): 1909–10PubMedCrossRef
9.
go back to reference Ghafouri M, Amini S, Khalili K, et al. HIV-1 associated dementia: symptoms and causes. Retrovirology 2006; 3: 28PubMedCrossRef Ghafouri M, Amini S, Khalili K, et al. HIV-1 associated dementia: symptoms and causes. Retrovirology 2006; 3: 28PubMedCrossRef
10.
go back to reference McArthur JC, Haughey N, Gartner S, et al. Human immunodeficiency virus-associated dementia: an evolving disease. J Neurovirol 2003 Apr; 9(2): 205–21PubMed McArthur JC, Haughey N, Gartner S, et al. Human immunodeficiency virus-associated dementia: an evolving disease. J Neurovirol 2003 Apr; 9(2): 205–21PubMed
11.
go back to reference Clifford DB. HIV-associated neurocognitive disease continues in the antiretroviral era. Top HIV Med 2008 Jun–Jul; 16(2): 94–8PubMed Clifford DB. HIV-associated neurocognitive disease continues in the antiretroviral era. Top HIV Med 2008 Jun–Jul; 16(2): 94–8PubMed
12.
go back to reference Tozzi V, Balestra P, Bellagamba R, et al. Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors. J Acquir Immune Defic Syndr 2007 Jun 1; 45(2): 174–82PubMedCrossRef Tozzi V, Balestra P, Bellagamba R, et al. Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors. J Acquir Immune Defic Syndr 2007 Jun 1; 45(2): 174–82PubMedCrossRef
13.
go back to reference Wynn HE, Brundage RC, Fletcher CV. Clinical implications of CNS penetration of antiretroviral drugs. CNS Drugs 2002; 16(9): 595–609PubMedCrossRef Wynn HE, Brundage RC, Fletcher CV. Clinical implications of CNS penetration of antiretroviral drugs. CNS Drugs 2002; 16(9): 595–609PubMedCrossRef
15.
go back to reference Coburn GA, Cullen BR. siRNAs: a new wave of RNA-based therapeutics. J Antimicrob Chemother 2003 Apr; 51(4): 753–6PubMedCrossRef Coburn GA, Cullen BR. siRNAs: a new wave of RNA-based therapeutics. J Antimicrob Chemother 2003 Apr; 51(4): 753–6PubMedCrossRef
16.
go back to reference Lee MT, Coburn GA, McClure MO, et al. Inhibition of human immunodeficiency virus type 1 replication in primary macrophages by using Tat- or CCR5-specific small interfering RNAs expressed from a lentivirus vector. J Virol 2003 Nov; 77(22): 11964–72PubMedCrossRef Lee MT, Coburn GA, McClure MO, et al. Inhibition of human immunodeficiency virus type 1 replication in primary macrophages by using Tat- or CCR5-specific small interfering RNAs expressed from a lentivirus vector. J Virol 2003 Nov; 77(22): 11964–72PubMedCrossRef
17.
go back to reference Han W, Wind-Rotolo M, Kirkman RL, et al. Inhibition of human immunodeficiency virus type 1 replication by siRNA targeted to the highly conserved primer binding site. Virology 2004 Dec 5; 330(1): 221–32PubMedCrossRef Han W, Wind-Rotolo M, Kirkman RL, et al. Inhibition of human immunodeficiency virus type 1 replication by siRNA targeted to the highly conserved primer binding site. Virology 2004 Dec 5; 330(1): 221–32PubMedCrossRef
18.
go back to reference Novina CD, Murray MF, Dykxhoorn DM, et al. siRNA-directed inhibition of HIV-1 infection. Nat Med 2002 Jul; 8(7): 681–6PubMed Novina CD, Murray MF, Dykxhoorn DM, et al. siRNA-directed inhibition of HIV-1 infection. Nat Med 2002 Jul; 8(7): 681–6PubMed
19.
go back to reference Nishitsuji H, Kohara M, Kannagi M, et al. Effective suppression of human immunodeficiency virus type 1 through a combination of short- or long-hairpin RNAs targeting essential sequences for retroviral integration. J Virol 2006 Aug; 80(15): 7658–66PubMedCrossRef Nishitsuji H, Kohara M, Kannagi M, et al. Effective suppression of human immunodeficiency virus type 1 through a combination of short- or long-hairpin RNAs targeting essential sequences for retroviral integration. J Virol 2006 Aug; 80(15): 7658–66PubMedCrossRef
20.
go back to reference Pomerantz RJ. RNA interference meets HIV-1: will silence be golden? Nat Med 2002 Jul; 8(7): 659–60PubMedCrossRef Pomerantz RJ. RNA interference meets HIV-1: will silence be golden? Nat Med 2002 Jul; 8(7): 659–60PubMedCrossRef
21.
go back to reference Liu YP, Haasnoot J, ter Brake O, et al. Inhibition of HIV-1 by multiple siRNAs expressed from a single microRNA polycistron. Nucleic Acids Res 2008 May; 36(9): 2811–24PubMedCrossRef Liu YP, Haasnoot J, ter Brake O, et al. Inhibition of HIV-1 by multiple siRNAs expressed from a single microRNA polycistron. Nucleic Acids Res 2008 May; 36(9): 2811–24PubMedCrossRef
22.
go back to reference Kumar P, Ban HS, Kim SS, et al. T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell 2008 Aug 22; 134(4): 577–86PubMedCrossRef Kumar P, Ban HS, Kim SS, et al. T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell 2008 Aug 22; 134(4): 577–86PubMedCrossRef
23.
go back to reference Song E, Zhu P, Lee SK, et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol 2005 Jun; 23(6): 709–17PubMedCrossRef Song E, Zhu P, Lee SK, et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol 2005 Jun; 23(6): 709–17PubMedCrossRef
24.
25.
go back to reference Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 2009 Feb; 8(2): 129–38PubMedCrossRef Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 2009 Feb; 8(2): 129–38PubMedCrossRef
26.
go back to reference Fischer D, Li Y, Ahlemeyer B, et al. In vitro cytotoxicity testing of polycations: influence of polymer structure on cell viability and hemolysis. Biomaterials 2003 Mar; 24(7): 1121–31PubMedCrossRef Fischer D, Li Y, Ahlemeyer B, et al. In vitro cytotoxicity testing of polycations: influence of polymer structure on cell viability and hemolysis. Biomaterials 2003 Mar; 24(7): 1121–31PubMedCrossRef
27.
go back to reference Kurreck J. RNA interference: from basic research to therapeutic applications. Angew Chem Int Ed Engl 2009; 48(8): 1378–98PubMedCrossRef Kurreck J. RNA interference: from basic research to therapeutic applications. Angew Chem Int Ed Engl 2009; 48(8): 1378–98PubMedCrossRef
28.
go back to reference Ortega P, Bermejo JF, Chonco L, et al. Novel water-soluble carbosilane dendrimers: synthesis and biocompatibility. Eur J Inorg Chem 2006; (7): 1388–96 Ortega P, Bermejo JF, Chonco L, et al. Novel water-soluble carbosilane dendrimers: synthesis and biocompatibility. Eur J Inorg Chem 2006; (7): 1388–96
29.
go back to reference Weber N, Ortega P, Clemente MI, et al. Characterization of carbosilane dendrimers as effective carriers of siRNA to HIV-infected lymphocytes. J Control Release 2008 Nov 24; 132(1): 55–64PubMedCrossRef Weber N, Ortega P, Clemente MI, et al. Characterization of carbosilane dendrimers as effective carriers of siRNA to HIV-infected lymphocytes. J Control Release 2008 Nov 24; 132(1): 55–64PubMedCrossRef
30.
go back to reference Fréchet JMJ. Dendrimers and other dendritic macromolecules: from building blocks to functional assemblies in nanoscience and nanotechnology. J Polymer Sci Part A: Polymer Chem 2003 Mar; 1758(3): 290–300 Fréchet JMJ. Dendrimers and other dendritic macromolecules: from building blocks to functional assemblies in nanoscience and nanotechnology. J Polymer Sci Part A: Polymer Chem 2003 Mar; 1758(3): 290–300
31.
go back to reference Loscher W, Potschka H. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog Neurobiol 2005 May; 76(1): 22–76PubMedCrossRef Loscher W, Potschka H. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog Neurobiol 2005 May; 76(1): 22–76PubMedCrossRef
32.
go back to reference Bermejo JF, Ortega P, Chonco L, et al. Water-soluble carbosilane dendrimers: synthesis biocompatibility and complexation with oligonucleotides; evaluation for medical applications. Chemistry 2007; 13(2): 483–95PubMedCrossRef Bermejo JF, Ortega P, Chonco L, et al. Water-soluble carbosilane dendrimers: synthesis biocompatibility and complexation with oligonucleotides; evaluation for medical applications. Chemistry 2007; 13(2): 483–95PubMedCrossRef
33.
go back to reference Chonco L, Bermejo-Martin JF, Ortega P, et al. Water-soluble carbosilane dendrimers protect phosphorothioate oligonucleotides from binding to serum proteins. Org Biomol Chem 2007 Jun 21; 5(12): 1886–93PubMedCrossRef Chonco L, Bermejo-Martin JF, Ortega P, et al. Water-soluble carbosilane dendrimers protect phosphorothioate oligonucleotides from binding to serum proteins. Org Biomol Chem 2007 Jun 21; 5(12): 1886–93PubMedCrossRef
34.
go back to reference Song E, Lee SK, Dykxhoorn DM, et al. Sustained small interfering RNA-mediated human immunodeficiency virus type 1 inhibition in primary macrophages. J Virol 2003 Jul; 77(13): 7174–81PubMedCrossRef Song E, Lee SK, Dykxhoorn DM, et al. Sustained small interfering RNA-mediated human immunodeficiency virus type 1 inhibition in primary macrophages. J Virol 2003 Jul; 77(13): 7174–81PubMedCrossRef
35.
go back to reference Capodici J, Kariko K, Weissman D. Inhibition of HIV-1 infection by small interfering RNA-mediated RNA interference. J Immunol 2002 Nov 1; 169(9): 5196–201PubMed Capodici J, Kariko K, Weissman D. Inhibition of HIV-1 infection by small interfering RNA-mediated RNA interference. J Immunol 2002 Nov 1; 169(9): 5196–201PubMed
36.
go back to reference Das AT, Brummelkamp TR, Westerhout EM, et al. Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. J Virol 2004 Mar; 78(5): 2601–5PubMedCrossRef Das AT, Brummelkamp TR, Westerhout EM, et al. Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. J Virol 2004 Mar; 78(5): 2601–5PubMedCrossRef
37.
go back to reference Toborek M, Lee YW, Flora G, et al. Mechanisms of the blood-brain barrier disruption in HIV-1 infection. Cell Mol Neurobiol 2005 Feb; 25(1): 181–99PubMedCrossRef Toborek M, Lee YW, Flora G, et al. Mechanisms of the blood-brain barrier disruption in HIV-1 infection. Cell Mol Neurobiol 2005 Feb; 25(1): 181–99PubMedCrossRef
38.
go back to reference Kuo YC, Chen HH. Effect of nanoparticulate polybutylcyanoacrylate and methylmethacrylate-sulfopropylmethacrylate on the permeability of zidovudine and lamivudine across the in vitro blood-brain barrier. Int J Pharm 2006 Dec 11; 327(1–2): 160–9PubMedCrossRef Kuo YC, Chen HH. Effect of nanoparticulate polybutylcyanoacrylate and methylmethacrylate-sulfopropylmethacrylate on the permeability of zidovudine and lamivudine across the in vitro blood-brain barrier. Int J Pharm 2006 Dec 11; 327(1–2): 160–9PubMedCrossRef
39.
go back to reference Hartig PC, Hunter 3rd ES. Gene delivery to the neurulating embryo during culture. Teratology 1998 Sep–Oct; 58(3–4): 103–12PubMedCrossRef Hartig PC, Hunter 3rd ES. Gene delivery to the neurulating embryo during culture. Teratology 1998 Sep–Oct; 58(3–4): 103–12PubMedCrossRef
40.
go back to reference Sata M, Walsh K. Endothelial cell apoptosis induced by oxidized LDL is associated with the down-regulation of the cellular caspase inhibitor FLIP. J Biol Chem 1998 Dec 11; 273(50): 33103–6PubMedCrossRef Sata M, Walsh K. Endothelial cell apoptosis induced by oxidized LDL is associated with the down-regulation of the cellular caspase inhibitor FLIP. J Biol Chem 1998 Dec 11; 273(50): 33103–6PubMedCrossRef
41.
go back to reference Kolchinsky P, Kiprilov E, Sodroski J. Increased neutralization sensitivity of CD4-independent human immunodeficiency virus variants. J Virol 2001 Mar; 75(5): 2041–50PubMedCrossRef Kolchinsky P, Kiprilov E, Sodroski J. Increased neutralization sensitivity of CD4-independent human immunodeficiency virus variants. J Virol 2001 Mar; 75(5): 2041–50PubMedCrossRef
42.
go back to reference Trillo-Pazos G, Diamanturos A, Rislove L, et al. Detection of HIV-1 DNA in microglia/macrophages, astrocytes and neurons isolated from brain tissue with HIV-1 encephalitis by laser capture microdissection. Brain Pathol 2003 Apr; 13(2): 144–54PubMedCrossRef Trillo-Pazos G, Diamanturos A, Rislove L, et al. Detection of HIV-1 DNA in microglia/macrophages, astrocytes and neurons isolated from brain tissue with HIV-1 encephalitis by laser capture microdissection. Brain Pathol 2003 Apr; 13(2): 144–54PubMedCrossRef
43.
go back to reference Alvarez Losada S, Canto-Nogues C, Munoz-Fernandez MA. A new possible mechanism of human immunodeficiency virus type 1 infection of neural cells. Neurobiol Dis 2002 Dec; 11(3): 469–78PubMedCrossRef Alvarez Losada S, Canto-Nogues C, Munoz-Fernandez MA. A new possible mechanism of human immunodeficiency virus type 1 infection of neural cells. Neurobiol Dis 2002 Dec; 11(3): 469–78PubMedCrossRef
44.
go back to reference Liu Y, Liu H, Kim BO, et al. CD4-independent infection of astrocytes by human immunodeficiency virus type 1: requirement for the human mannose receptor. J Virol 2004 Apr; 78(8): 4120–33PubMedCrossRef Liu Y, Liu H, Kim BO, et al. CD4-independent infection of astrocytes by human immunodeficiency virus type 1: requirement for the human mannose receptor. J Virol 2004 Apr; 78(8): 4120–33PubMedCrossRef
45.
go back to reference Jevprasesphant R, Penny J, Jalal R, et al. The influence of surface modification on the cytotoxicity of PAMAM dendrimers. Int J Pharm 2003 Feb 18; 252(1–2): 263–6PubMedCrossRef Jevprasesphant R, Penny J, Jalal R, et al. The influence of surface modification on the cytotoxicity of PAMAM dendrimers. Int J Pharm 2003 Feb 18; 252(1–2): 263–6PubMedCrossRef
46.
go back to reference Vogelbaum MA, Tong JX, Higashikubo R, et al. Transfection of C6 glioma cells with the bax gene and increased sensitivity to treatment with cytosine arabinoside. J Neurosurg 1998 Jan; 88(1): 99–105PubMedCrossRef Vogelbaum MA, Tong JX, Higashikubo R, et al. Transfection of C6 glioma cells with the bax gene and increased sensitivity to treatment with cytosine arabinoside. J Neurosurg 1998 Jan; 88(1): 99–105PubMedCrossRef
47.
go back to reference Lampela P, Soininen P, Urtti A, et al. Synergism in gene delivery by small PEIs and three different nonviral vectors. Int J Pharm 2004 Feb 11; 270(1–2): 175–84PubMedCrossRef Lampela P, Soininen P, Urtti A, et al. Synergism in gene delivery by small PEIs and three different nonviral vectors. Int J Pharm 2004 Feb 11; 270(1–2): 175–84PubMedCrossRef
48.
go back to reference Alvarez S, Jimenez JL, Serramia MJ, et al. Lack of association of HIV-1 biological or molecular properties with neurotropism for brain cells. J Mol Neurosci 2006; 29(2): 131–44PubMedCrossRef Alvarez S, Jimenez JL, Serramia MJ, et al. Lack of association of HIV-1 biological or molecular properties with neurotropism for brain cells. J Mol Neurosci 2006; 29(2): 131–44PubMedCrossRef
49.
go back to reference Gorry PR, Bristol G, Zack JA, et al. Macrophage tropism of human immunodeficiency virus type 1 isolates from brain and lymphoid tissues predicts neurotropism independent of coreceptor specificity. J Virol 2001 Nov; 75(21): 10073–89PubMedCrossRef Gorry PR, Bristol G, Zack JA, et al. Macrophage tropism of human immunodeficiency virus type 1 isolates from brain and lymphoid tissues predicts neurotropism independent of coreceptor specificity. J Virol 2001 Nov; 75(21): 10073–89PubMedCrossRef
50.
go back to reference MacKay JA, Deen DF, Szoka Jr FC. Distribution in brain of liposomes after convection enhanced delivery: modulation by particle charge, particle diameter, and presence of steric coating. Brain Res 2005 Feb 28; 1035(2): 139–53PubMedCrossRef MacKay JA, Deen DF, Szoka Jr FC. Distribution in brain of liposomes after convection enhanced delivery: modulation by particle charge, particle diameter, and presence of steric coating. Brain Res 2005 Feb 28; 1035(2): 139–53PubMedCrossRef
51.
go back to reference Lockman PR, Koziara JM, Mumper RJ, et al. Nanoparticle surface charges alter blood-brain barrier integrity and permeability. J Drug Target 2004; 12(9–10): 635–41PubMedCrossRef Lockman PR, Koziara JM, Mumper RJ, et al. Nanoparticle surface charges alter blood-brain barrier integrity and permeability. J Drug Target 2004; 12(9–10): 635–41PubMedCrossRef
52.
go back to reference Fenart L, Casanova A, Dehouck B, et al. Evaluation of effect of charge and lipid coating on ability of 60-nm nanoparticles to cross an in vitro model of the blood-brain barrier. J Pharmacol Exp Ther 1999 Dec; 291(3): 1017–22PubMed Fenart L, Casanova A, Dehouck B, et al. Evaluation of effect of charge and lipid coating on ability of 60-nm nanoparticles to cross an in vitro model of the blood-brain barrier. J Pharmacol Exp Ther 1999 Dec; 291(3): 1017–22PubMed
53.
go back to reference Huang RQ, Qu YH, Ke WL, et al. Efficient gene delivery targeted to the brain using a transferrin-conjugated polyethyleneglycol-modified polyamidoamine dendrimer. Faseb J 2007 Apr; 21(4): 1117–25PubMedCrossRef Huang RQ, Qu YH, Ke WL, et al. Efficient gene delivery targeted to the brain using a transferrin-conjugated polyethyleneglycol-modified polyamidoamine dendrimer. Faseb J 2007 Apr; 21(4): 1117–25PubMedCrossRef
54.
go back to reference Dehouck B, Fenart L, Dehouck MP, et al. A new function for the LDL receptor: transcytosis of LDL across the blood-brain barrier. J Cell Biol 1997 Aug 25; 138(4): 877–89PubMedCrossRef Dehouck B, Fenart L, Dehouck MP, et al. A new function for the LDL receptor: transcytosis of LDL across the blood-brain barrier. J Cell Biol 1997 Aug 25; 138(4): 877–89PubMedCrossRef
55.
go back to reference Balazs Z, Panzenboeck U, Hammer A, et al. Uptake and transport of high-density lipoprotein (HDL) and HDL-associated alpha-tocopherol by an in vitro blood-brain barrier model. J Neurochem 2004 May; 89(4): 939–50PubMedCrossRef Balazs Z, Panzenboeck U, Hammer A, et al. Uptake and transport of high-density lipoprotein (HDL) and HDL-associated alpha-tocopherol by an in vitro blood-brain barrier model. J Neurochem 2004 May; 89(4): 939–50PubMedCrossRef
56.
go back to reference Yousif S, Marie-Claire C, Roux F, et al. Expression of drug transporters at the blood-brain barrier using an optimized isolated rat brain microvessel strategy. Brain Res 2007 Feb 23; 1134(1): 1–11PubMedCrossRef Yousif S, Marie-Claire C, Roux F, et al. Expression of drug transporters at the blood-brain barrier using an optimized isolated rat brain microvessel strategy. Brain Res 2007 Feb 23; 1134(1): 1–11PubMedCrossRef
57.
go back to reference Giovannoni G, Miller RF, Heales SJ, et al. Elevated cerebrospinal fluid and serum nitrate and nitrite levels in patients with central nervous system complications of HIV-1 infection: a correlation with blood-brain-barrier dysfunction. J Neurol Sci 1998; 156(1): 53–8PubMedCrossRef Giovannoni G, Miller RF, Heales SJ, et al. Elevated cerebrospinal fluid and serum nitrate and nitrite levels in patients with central nervous system complications of HIV-1 infection: a correlation with blood-brain-barrier dysfunction. J Neurol Sci 1998; 156(1): 53–8PubMedCrossRef
58.
go back to reference Petito CK, Cash KS. Blood-brain barrier abnormalities in the acquired immunodeficiency syndrome: immunohistochemical localization of serum proteins in postmortem brain. Ann Neurol 1992 Nov; 32(5): 658–66PubMedCrossRef Petito CK, Cash KS. Blood-brain barrier abnormalities in the acquired immunodeficiency syndrome: immunohistochemical localization of serum proteins in postmortem brain. Ann Neurol 1992 Nov; 32(5): 658–66PubMedCrossRef
Metadata
Title
Carbosilane Dendrimers to Transfect Human Astrocytes with Small Interfering RNA Targeting Human Immunodeficiency Virus
Authors
Jose Luis Jiménez
María Isabel Clemente
Nick D. Weber
Javier Sanchez
Paula Ortega
F. Javier de la Mata
Rafael Gómez
Dolores García
Luis A. López-Fernández
Dr María Ángeles Muñoz-Fernández
Publication date
01-10-2010
Publisher
Springer International Publishing
Published in
BioDrugs / Issue 5/2010
Print ISSN: 1173-8804
Electronic ISSN: 1179-190X
DOI
https://doi.org/10.2165/11538400-000000000-00000

Other articles of this Issue 5/2010

BioDrugs 5/2010 Go to the issue

Adis Drug Profile

Pazopanib